TipRanks
Tvardi Therapeutics (DE:69C)
FRANKFURT:69C
Germany Market
69C
Tvardi Therapeutics
RESEARCH TOOLSreports

Tvardi Therapeutics (69C) Income Statement

1 Followers

Tvardi Therapeutics Income Statement

Last quarter (Q2 2026), Tvardi Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Tvardi Therapeutics's net income was $-6.46M. See Tvardi Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 7.14M$ 20.97M$ 41.87M$ 23.03M
Gross Profit
$ -95.00K$ 6.33M$ 14.54M$ 34.35M$ 21.47M
Operating Expenses
$ 26.75M$ 62.11M$ 136.03M$ 121.89M$ 110.56M
Depreciation and Amortization
$ 95.00K$ 192.00K$ 259.00K$ 1.67M$ 1.55M
EBITDA
$ -18.12M$ -62.60M$ -117.65M$ -83.80M$ -86.89M
Operating Income
$ -26.75M$ -55.78M$ -121.50M$ -87.53M$ -89.08M
Other Income/Expenses
$ 8.53M$ -15.48M$ 2.98M$ 2.06M$ 642.00K
Pretax Income
$ -18.21M$ -71.27M$ -118.51M$ -85.47M$ -88.44M
Net Income
$ -18.21M$ -70.87M$ -118.51M$ -85.47M$ -88.44M
Per Share Metrics
Basic EPS
$ -2.46$ -46.59$ -1.85$ -2.20$ -62.77
Diluted EPS
$ -3.26$ -46.59$ -1.85$ -2.20$ -62.77
Weighted Average Shares Outstanding
 7.42M 1.52M 9.36M 9.36M 1.41M
Weighted Average Shares Outstanding (Diluted)
 7.78M 1.52M 9.36M 9.36M 1.41M
Currency in USD

Tvardi Therapeutics Earnings and Revenue History